Project description
Advancing psoriatic arthritis diagnosis and management
Psoriasis is an autoimmune skin condition associated with the emergence of red, dry, itchy patches mainly on elbows, knees and scalp. Some patients with psoriasis develop a type of inflammatory arthritis known as psoriatic arthritis (PsA), which can cause swelling and stiffness in the joints. However, diagnosis of PsA is difficult, and there is no way to predict which patients will develop the condition or how they will respond to treatment. HIPPOCRATES is a large EU-funded project that brings together research, clinical and industry experts to determine the mechanisms of PsA development and progression. Project findings will fuel future drug discovery efforts for disease management and improved patient outcomes.
Objective
Psoriatic Arthritis (PsA) is a clinically heterogeneous disease associated with diminished quality of life. Early diagnosis is challenging and prediction of natural history or therapeutic response to treatment is suboptimal: these represent critical, contemporary unmet clinical needs. HIPPOCRATES is a multi-centre consortium, with 26 world-class partners that have clinical, scientific, data analytics, ethics, patient participation and pharmaceutical industry expertise. We will address these needs. Clinical phenotypic data from multiple established, and de novo PsA cohorts combined with a unique library of bio- samples, images, and data derived therefrom, will be curated and catalogued for optimal evaluation and use. HIPPOCRATES will analyse these multi-structured datasets that traverse the disease timeline, from cutaneous psoriasis, early PsA, first therapeutic and first biologic choice. Through machine learning and other AI techniques, we will: (1) Identify molecular signals associated with the development of PsA in patients with psoriasis, so presaging PsA prevention studies; (2) Create a diagnostic algorithm for early PsA diagnosis in patients with cutaneous psoriasis or early undifferentiated inflammatory arthritis; (3) Generate biomarker algorithms, including clinical, imaging and molecular polyomic moieties, to predict disease progression and identify endotypes permitting precision treatment with existing (methotrexate, and TNF or IL-17 inhibitor) treatments and novel therapeutic regimes; (4) Elucidate the molecular basis of PsA to facilitate future drug discovery; (5) Develop diagnostic digital tools for use in clinical settings. With highly aligned academic/clinical, SME and EFPIA partners, including involvement from existing IMI programmes and competitive international associations, HIPPOCRATES will oversee the development of a sustainable infrastructure to support PsA research and improve PsA patient outcomes.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
4 Dublin
Ireland
See on map
Participants (28)
G12 8QQ Glasgow
See on map
91054 Erlangen
See on map
9052 ZWIJNAARDE - GENT
See on map
80686 Munchen
See on map
3000 Leuven
See on map
M13 9PL Manchester
See on map
OX1 2JD Oxford
See on map
A96 E8H2 DUBLIN
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
66386 St Ingbert
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
08036 Barcelona
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
08036 Barcelona
See on map
3400 Hillerod
See on map
20123 Milano
See on map
1435 HW Rijsenhout
See on map
8802 Kilchberg
See on map
1206 Geneve
See on map
9860 OOSTERZELE
See on map
1081 HV Amsterdam
See on map
OX4 2WB Oxford
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
100 44 Stockholm
See on map
WC2R 2LS London
See on map
Participation ended
WA15 9AF Hale Altrincham
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4056 Basel
See on map
1070 Bruxelles / Brussel
See on map
10154 New York
See on map
CT13 9NJ Sandwich
See on map
MK8 0AB Milton Keynes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
60064 North Chicago Il
See on map